Drugmaker shares drop after RFK Jr. tapped to lead HHS - The Hill
| DOD Stock | 1.95 0.01 0.51% |
About 61% of DOD Biotech's investor base is looking to short. The analysis of current outlook of investing in DOD Biotech Public suggests that many traders are alarmed regarding DOD Biotech's prospects. DOD Biotech's investing sentiment shows overall attitude of investors towards DOD Biotech Public.
DOD |
Drugmaker shares drop after RFK Jr. tapped to lead HHS The Hill
Read at news.google.com
 |
DOD Biotech Fundamental Analysis
We analyze DOD Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DOD Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DOD Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
DOD Biotech is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
DOD Biotech Public Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with DOD Biotech stock to make a market-neutral strategy. Peer analysis of DOD Biotech could also be used in its relative valuation, which is a method of valuing DOD Biotech by comparing valuation metrics with similar companies.
Peers
DOD Biotech Related Equities
| KCE | KCE Electronics | 0.83 |
| ||
| CBG | Carabao Group | 1.24 |
| ||
| JMART | Jay Mart | 1.45 |
| ||
| GULF | Gulf Energy | 2.00 |
| ||
| MEGA | Mega Lifesciences | 4.32 |
|
Other Information on Investing in DOD Stock
DOD Biotech financial ratios help investors to determine whether DOD Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOD with respect to the benefits of owning DOD Biotech security.